Telix Pharmaceuticals Ltd ADR TLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $11.02
- Day Range
- $11.08–11.29
- 52-Week Range
- $6.28–16.94
- Bid/Ask
- $10.00 / $11.32
- Shares Outstanding
- 338.78M
- Market Cap
- $3.82B
- Volume/Avg
- 61,910 / 183,308
Key Statistics
- Price/Earnings (Normalized)
- 2,020.40
- Price/Sales
- 4.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,184
- Website
- https://www.telixpharma.com
Competitors
Valuation
|
Metric
|
TLX
|
CSL
|
NVS
|
|---|---|---|---|
Price/Earnings (Normalized) | 2,020.40 | 11.36 | 17.35 |
Price/Book Value | 9.21 | 2.11 | 7.47 |
Price/Sales | 4.55 | 2.48 | 5.17 |
Price/Cash Flow | — | 10.76 | 14.79 |
Price/Earnings
TLX
CSL
NVS
Financial Strength
|
Metric
|
TLX
|
CSL
|
NVS
|
|---|---|---|---|
Quick Ratio | 1.21 | 1.12 | 0.53 |
Current Ratio | 1.43 | 2.57 | 0.85 |
Interest Coverage | 0.73 | 9.23 | 13.66 |
Quick Ratio
TLX
CSL
NVS
Profitability
|
Metric
|
TLX
|
CSL
|
NVS
|
|---|---|---|---|
Return on Assets (Normalized) | −1.31% | — | 15.46% |
Return on Equity (Normalized) | −3.61% | — | 39.95% |
Return on Invested Capital (Normalized) | 1.22% | — | 22.43% |
Return on Assets
TLX
CSL
NVS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&#$^&? | LOCK|C#G#> | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|bg&?^< | LOCK|%QhD< | $70B | |||
| argenx SE ADR
ARGX
| LOCK|#L#K@#D | LOCK|Ym | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|hR!jD^@ | LOCK|dNM^& | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?XWt?r | LOCK|$s^ | $37B | |||
| Moderna Inc
MRNA
| LOCK|<WQGN& | LOCK|Tw | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|h^<S<?%% | LOCK|Z>My | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|$!%qHwK | LOCK|?X$ | $23B | |||
| Incyte Corp
INCY
| LOCK|>L<v%y$ | LOCK|f> | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<r@r@l! | LOCK|^% | $16B |
United States